Search

Meet Achille Iolascon, our Volunteer of the Month

Can you tell us what you do for EHA and when you started?
I serve the EHA as chairman of the Study working group on “Red cells and iron” since June 2014.

Read more

The European Union must deliver funding for research of blood disorders

At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.

Read more

SWG Educational Activities

SWG meeting, EHA2023 CongressGuidelines SessionSession title‘The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

Abstract submission

The official abstract submission is now closed.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more